Alterity therapeutics presents ath434-201 phase 2 clinical trial results at european msa symposium

Melbourne, australia and san francisco, april 28, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that david stamler, m.d., chief executive officer presented the ath434-201 phase 2 clinical trial results at the annual msa research symposium hosted by university college london, institute of neurology in partnership with the msa trust of the u.k.
MSA Ratings Summary
MSA Quant Ranking